Drugs / P-CD19CD20-ALLO1
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07008378 | Oct 2025 → Aug 2032 expected | multiple sclerosis | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06014762 | Apr 2024 → Mar 2029 expected | high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma | Poseida Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P-CD19CD20-ALLO1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07008378 ↗ |
| Modality | Cell therapy | “allogeneic T stem cell memory (Tscm) CAR-T cells” NCT06014762 ↗ |
| Route | Intravenous | “Single weight-based IV administration” NCT06014762 ↗ |